Melatonin, a promising role in taxane-related neuropathy

Clinical Medicine Insights: Oncology

Volumn 4, Issue , 2010, Pages 35-41

  Nahleh, Z ^a   Pruemer, J ^b   Lafollette, J ^c   Sweany, S ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c GRADY HEALTH SYSTEM   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Melatonin; Neuropathy; Quality of life; Taxane

Indexed keywords

DOCETAXEL; MELATONIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; SEDATION; SIDE EFFECT;

EID: 77952363292     PISSN: None     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/cmo.s4132     Document Type: Article

References (24)

1. Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer. 2004;11:82-5.
2. Guastalla JP, Dieras V. The taxanes: toxicity and quality of life consideration in advanced ovarian cancer. Br J Cancer. 2003;89:S16-22.
3. Rowinski E, Donehower R. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004-14.
4. Postma T, Vermorket J, Liefting A, et al. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6:489-94.
5. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. European Journal of Cancer. 2006;42:24-30.
6. Jones S, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. Journal Clin Oncol. 2005;23:5542-51.
7. Gradishar W, Sergei T, Davidson N, et al. Superior efficacy of albumin- bound paclitaxel, ABI-007 compared with polyethylated castor-oil based paclitaxel in women with metastatic breast cancer: results from a phase III trial. Journal Clin Oncol. 2005;23:1-10.
8. Makino H. Treatment and care of neurotoxicity from taxane anticancer agents. Breast Cancer. 2004;11:100-4.
9. Freilich RF, Balmaceda C, Seidman AD, et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996;47:115-8.
10. Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and cisplatin-induced neurotoxicity: a prospective role of acetyl-L-carnitine. Clin Cancer Res. 2003;9:5756-67.
11. Loven D, Levavi H, Sabach G, et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. European Journal of Cancer Care. 2009;18(1):78-83.
12. Rogerio F, Teixeira S, Santos de Rezende A, et al. Superoxide dismutase isoforms 1 and 2 in lumbar spinal cord of neonatal rats after sciatic nerve transaction and melatonin treatment. Development Brain Research. 2005;154:217-25.
13. Chang HM, Ling E, Chen C, et al. Melatonin attenuates the neuronal NADPH-d/NOS expression in the nodose ganglion of acute hypoxic rats. J pineal Res. 2002;32:65-73.
14. Lissoni P, Tancini G, Barni S, et al. Treatment of cancer chemotherapy- induced toxicity with the pineal hormone melatonin. Support Care Cancer. 1997;5:126-9.
15. Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J pineal Res. 1997;23:15-9.
16. Sarma A, Rodriguez M, Cabanillas F, et al. A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma. Jourl Clin Oncol. 2004;22:8066.
17. National Cancer Institute Common terminology criteria for adverse events v3.0ctep.cancer.gov/forms/CTCAEv3.pdf (accessed 2008 Mar 22).
18. http://www.facit.org/ (accessed 2009 October 17).
19. Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr. 1997;24:223-31.
20. Cagnacci A, Serenella A, Renzi A, et al. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clinical Endocrinology. 2001;54:339-46.
21. Claustrat B, Brun J, David M, et al. Melatonin and jet lag: confirmatory result using a simplified protocol. Biol psychiatry. 1992;32:705-11.
22. Deacon S, English J, Arendt J. Acute phase-shifting effects of melatonin associated with suppression of core body temperature in humans. Neuroscience. 1994;178:32-4.
23. Dahlitz M, Alvarez B, Vignau J, et al. Delayed sleep phase syndrome response to melatonin. Lancet. 1991;337:1121-4.
24. Shaw KM. Hypothalamo-pituitary-adrenal function in Parkinsoinian patients treated with melatonin. Curr Med Res Opin. 1977;4:743-6.